Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aprotinin

S Robert1, B K Wagner, M Boulanger

  • 1Pfizer-Canada, Pointe-Claire, Québec.

The Annals of Pharmacotherapy
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

Aprotinin effectively reduces bleeding during coronary artery bypass graft (CABG) surgery by preserving platelet function and inhibiting fibrinolysis. Further research is needed to fully define its indications, dosing, and safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flexible Ansatz for <i>N</i>-Body Perturbation Theory.

The journal of physical chemistry. A·2024
Same author

Coupled cluster-inspired geminal wavefunctions.

The Journal of chemical physics·2024
Same author

Agricultural exposures and DNA damage in PBMC of female farmers measured using the alkaline comet assay.

International archives of occupational and environmental health·2024
Same author

The Management of Persistent Distal Occlusions after Mechanical Thrombectomy and Thrombolysis: An Inter- and Intrarater Agreement Study.

AJNR. American journal of neuroradiology·2024
Same author

Pesticide exposure in greenspaces: Comparing field measurement of dermal contamination with values predicted by registration models.

The Science of the total environment·2024
Same author

Revisiting the historical scenario of a disease dissemination using genetic data and Approximate Bayesian Computation methodology: The case of <i>Pseudocercospora fijiensis</i> invasion in Africa.

Ecology and evolution·2023
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiothoracic Surgery
  • Hemostasis

Background:

  • Aprotinin is a serine protease inhibitor derived from bovine lung tissue.
  • It is utilized in surgical procedures with significant blood loss, particularly coronary artery bypass graft (CABG) surgery.
  • Understanding its clinical pharmacology is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To review the clinical pharmacology of aprotinin.
  • To assess its efficacy and safety in patients undergoing procedures with major blood loss, specifically CABG.
  • To synthesize current evidence on aprotinin's mechanisms and applications.

Main Methods:

  • Comprehensive MEDLINE search for English and French publications on aprotinin in cardiothoracic surgery and hemorrhage.

Related Experiment Videos

  • Inclusion of data from Canadian and US product labels.
  • Review of abstracts, uncontrolled, and controlled clinical trials, extracting data on design, population, results, and safety.

    • Main Results:

    • Aprotinin demonstrates antifibrinolytic activity and preserves platelet function, thereby decreasing blood loss post-cardiac surgery.
    • Clinical trials confirm reduced blood loss and transfusion needs in CABG patients.
    • While generally well-tolerated with rare allergic reactions, concerns exist regarding a potential prothrombotic state.

    Conclusions:

    • Aprotinin is established as an effective hemostatic agent for CABG procedures.
    • Further investigation is required to thoroughly define optimal indications, dosing strategies, safety considerations, and the implications of repeated administration.